Free Trial

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences logo
$4.03 -0.43 (-9.64%)
(As of 04:00 PM ET)

Solid Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
12

Based on 12 Wall Street analysts who have issued ratings for Solid Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 8 have given a buy rating, and 4 have given a strong buy rating for SLDB.

Consensus Price Target

$15.22
277.72% Upside
According to the 12 analysts' twelve-month price targets for Solid Biosciences, the average price target is $15.22. The highest price target for SLDB is $20.00, while the lowest price target for SLDB is $12.00. The average price target represents a forecasted upside of 277.72% from the current price of $4.03.
Get the Latest News and Ratings for SLDB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Solid Biosciences and its competitors.

Sign Up

SLDB Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
4 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.22$15.14$15.67$9.00
Forecasted Upside277.72% Upside202.86% Upside95.83% Upside67.91% Upside
Consensus Rating
Buy
Buy
Buy
Buy

SLDB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SLDB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Solid Biosciences Stock vs. The Competition

TypeSolid BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.33
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside258.17% Upside28,319.66% Upside12.03% Upside
News Sentiment Rating
Positive News

See Recent SLDB News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/13/2024Wedbush
4 of 5 stars
 Initiated CoverageOutperform$16.00+241.88%
12/12/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00+219.36%
12/10/2024Citizens Jmp
0 of 5 stars
S. Tuerkcan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$15.00+193.54%
11/12/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$15.00 ➝ $12.00+108.33%
11/11/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00+150.42%
8/30/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/14/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$18.00 ➝ $15.00+80.07%
6/24/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$12.00 ➝ $12.00+85.76%
6/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00+203.03%
3/15/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+30.29%
9/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:11 PM ET.


SLDB Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Solid Biosciences is $15.22, with a high forecast of $20.00 and a low forecast of $12.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 8 buy ratings and 4 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLDB shares.

According to analysts, Solid Biosciences's stock has a predicted upside of 277.72% based on their 12-month stock forecasts.

Over the previous 90 days, Solid Biosciences's stock had 2 upgrades by analysts.

Solid Biosciences has been rated by research analysts at Chardan Capital, Citizens Jmp, HC Wainwright, JMP Securities, JPMorgan Chase & Co., and Wedbush in the past 90 days.

Analysts like Solid Biosciences more than other "medical" companies. The consensus rating for Solid Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SLDB compares to other companies.


This page (NASDAQ:SLDB) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners